Melchardt, Thomas <br/><br/>
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.  [electronic resource] 

 -  BMC cancer  Oct 2015 
 - 725 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-015-1776-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Docetaxel<br/>Female<br/>Fluorouracil--administration & dosage<br/>Genotype<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Induction Chemotherapy--adverse effects<br/>Male<br/>Middle Aged<br/>Polymorphism, Genetic<br/>Polymorphism, Single Nucleotide<br/>Steroid Hydroxylases--genetics<br/>Taxoids--administration & dosage